Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products
TAN Hongbin,JIANG Qijun,WU Jianxiang,LIANG Chun,LIU Xing,REN Yusheng,WU Zonggui
2009-01-01
Abstract:Objective To investigate whether peroxisome proliferator-activated receptor-gamma(PPARγ)agonists rosiglitazone can ameliorate the dysfunction of endothelial progenitor cells(EPCs)induced by advanced glycation end products(AGEs).Methods EPCs isolated from healthy adults were cultured with various concentrations of advanced glycation end product-human serum albumin(AGE-HSA)(0,50,100 and 200 mg/L)for 24 h in the absence or presence of rosiglitazone(10 nmol/L),anti-RAGE antibody(50 mg/L).We also included a blank control group.The proliferation,apoptosis,cell adhesion,migration,NO production and vascular cell adhesion molecule(VCAM)-1 secretion by EPCs were assessed.Results AGE-HSA at 200 mg/L significantly impaired the proliferation(reduced by [37.7±6.3]% compared with control,P<0.05),adherent([35.6±1.5]/HPF vs.[20.2±1.3]/HPF,P<0.05),and migration([28.6±2.8]/HPF vs.[15.0±2.1]/HPF,P<0.05)of EPCs,and aggravated the apoptosis([4.6±0.8]% vs.[15.2±1.0]%,P<0.05)of EPCs.Rosiglitazone significantly reversed the impairment effect of AGE-HSA on the proliferation(increased to [89.3±5.9]%,P<0.05),adherent(increased to [31.2±2.6]/HPF,P<0.05)and migration(increased to [21.6±3.1]/HPF,P<0.05)of EPCs,and ameliorated the apoptosis(reduced to [6.1±0.9]%,P<0.05)of EPCs.Rosiglitazone also increased the production of NO([16.2±1.0]μmol/L vs.[10.2±0.5] μmol/L,P<0.05)and reduced the secretion of VCAM-1([5.2±0.04] μg/L vs.[6.2±0.1] μg/L,P<0.05)of EPCs.Conclusion PPARγ agonist rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products.